奥普科健康
OPK
1.53
-0.08
-4.97%
奥普科健康
US · OPK
#3224 按市值排名
1.53
-0.08
-4.97%
实时 - 追踪5344个代码 - 心跳于138秒前
· 2026-10-16 19:58
✦ 量化股权信号 计算方式说明
增持
- 最近一期（2026/Q3）披露持股的机构数量减少了4家。
- 机构持股总比例上升了0.3个百分点。
机构持股
- 机构持股比例
- 34.91% +0.29pp
- 机构数量
- 259 -4
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Individual/Insider43.22%
Mutual Fund18.14%
Hedge Fund8.28%
VC/PE Fund4.04%
Private Company3.26%
Public Company0.62%
Family Office/Trust0.23%
Government Pension Fund0.22%
Insurance Company0.11%
Other21.88%
主要股东 截至 2026-06-29
Phillip Frost
29.45% · 219.78M 股
Rubric Capital Management LP
6.40% · 47.79M 股
Gary Nabel
5.40% · 40.31M 股
BlackRock
4.95% · 36.98M 股
Jane Hsiao
4.44% · 33.13M 股
Frost Group, LLC
4.04% · 30.13M 股
Elias Zerhouni
2.74% · 20.42M 股
Eaz Zeraz Trust
2.65% · 19.78M 股
Vanguard Capital Management, LLC
2.37% · 17.68M 股
Vanguard Portfolio Management, LLC
2.00% · 14.93M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 45次买入 · 3次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Phillip Frost | Chairperson & CEO | 29.45% |
| Gary Nabel | Chief Innovation Officer & Director | 5.40% |
| Jane Hsiao | Vice Chairman of the Board & Chief Technical Officer | 4.44% |
| Elias Zerhouni | President & Vice Chairman of the Board | 2.74% |
| Steven Rubin | Executive VP of Administration & Director | 0.85% |
| Subbarao Uppaluri | Independent Director | 0.16% |
| John Paganelli | Independent Director | 0.05% |
| Adam Logal | Senior VP, CFO, Chief Accounting Officer & Treasurer | 0.05% |
| Richard Pfenniger | Lead Independent Director | 0.04% |
| Lin-Tsing Yu | Independent Director | 0.01% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-07-23 | Steven Rubin | Executive VP of Administration & Director | Sale to Issuer | -53,266 | $1.22 |
| 2026-07-23 | Adam Logal | Senior VP, CFO, Chief Accounting Officer & Treasurer | Sale to Issuer | -53,266 | $1.22 |
| 2026-06-17 | Roger Medel | Independent Director | Other Derivative Acquisition | +30,000 | $1.42 |
| 2026-06-17 | Richard Pfenniger | Lead Independent Director | Other Derivative Acquisition | +60,000 | $1.42 |
| 2026-06-17 | John Paganelli | Independent Director | Other Derivative Acquisition | +30,000 | $1.42 |
| 2026-06-17 | Prem Lachman | Independent Director | Other Derivative Acquisition | +30,000 | $1.42 |
| 2026-06-17 | Subbarao Uppaluri | Independent Director | Other Derivative Acquisition | +80,000 | $1.42 |
| 2026-06-17 | Lin-Tsing Yu | Independent Director | Other Derivative Acquisition | +30,000 | $1.42 |
| 2026-03-19 | John Paganelli | Independent Director | Open Market Acquisition | +10,000 | $1.14 |
| 2026-03-17 | Subbarao Uppaluri | Independent Director | Other Derivative Acquisition | +50,000 | $1.17 |
| 2026-03-17 | Subbarao Uppaluri | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Uppaluri Investments LLC | -- | Initial Statement of Beneficial | 0 | -- |
| 2025-11-20 | Phillip Frost | Chairperson & CEO | Open Market Acquisition | +580,000 | $1.30–1.34 |
| 2025-11-19 | Phillip Frost | Chairperson & CEO | Open Market Acquisition | +580,000 | $1.32–1.35 |
| 2025-11-18 | Phillip Frost | Chairperson & CEO | Open Market Acquisition | +580,000 | $1.28–1.32 |
| 2025-11-17 | Phillip Frost | Chairperson & CEO | Other Acquisition | +46,700 | $1.26 |
| 2025-11-17 | Phillip Frost | Chairperson & CEO | Open Market Acquisition | +533,300 | $1.25–1.29 |
| 2025-10-30 | Phillip Frost | Chairperson & CEO | Open Market Acquisition | +150,000 | $1.42 |
| 2025-08-17 | Phillip Frost | Chairperson & CEO | Other Disposition | -440,000 | -- |
| 2025-08-07 | Phillip Frost | Chairperson & CEO | Open Market Acquisition | +675,000 | $1.32 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:58:57 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
奥普科健康 讨论区 0 条评论